Eli Lilly's stock plummeted nearly 10% in premarket trading after the company reported Q3 earnings that fell short of Wall Street expectations, with revenue at $11.4 billion against estimates of $12.17 billion. Despite a 20% year-over-year increase, the company cut its profit guidance and revenue outlook, citing inventory decreases impacting sales of its weight-loss drug Zepbound and diabetes drug Mounjaro. The combined sales from these drugs reached $4.4 billion, but Zepbound's revenue missed analyst estimates, raising concerns about the stock's future in a complex healthcare market.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
